Go Back to Match Results for ""
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Study Overview
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments
Study Description
(BYLieve) A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after prior treatments
- ClinicalTrials.gov Identifier: NCT03056755
- Protocol Number: 17-603
- Principal Investigator: Gerburg Wulf
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required